We are live on
!
Find out more
Jacobs Levy Equity Management Portfolio holdings
AUM
$23.8B
1-Year Est. Return
25.4%
This Fund
S&P 500
This Quarter
Est. Return
+15.41%
1 Year Est. Return
+25.4%
3 Year Est. Return
+87.35%
5 Year Est. Return
+125.75%
10 Year Est. Return
+515.94%
AUM
$6.93B
AUM Growth
+$1.24B
(+22%)
Cap. Flow
+$454M
Cap. Flow
% of AUM
6.54%
Top 10 Holdings %
Top 10 Hldgs %
16.4%
Holding
1,110
New
146
Increased
497
Reduced
266
Closed
160
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVR
NVR
|
+$34.9M |
| 2 |
SBA Communications
SBAC
|
+$31.5M |
| 3 |
Lennox International
LII
|
+$29.1M |
| 4 |
McKesson
MCK
|
+$24.8M |
| 5 |
Cable One
CABO
|
+$23.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$55.8M |
| 2 |
WCG
Wellcare Health Plans, Inc.
WCG
|
+$52.7M |
| 3 |
Vertex Pharmaceuticals
VRTX
|
+$42.5M |
| 4 |
Intuitive Surgical
ISRG
|
+$35.5M |
| 5 |
XLNX
Xilinx Inc
XLNX
|
+$33.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.87% |
| 2 | Financials | 16.58% |
| 3 | Consumer Discretionary | 13.8% |
| 4 | Industrials | 12.36% |
| 5 | Healthcare | 10.52% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
851
Protagonist Therapeutics
PTGX
$8.82B
| $273K | ﹤0.01% |
21,700
-6,700
| -24% | -$59.1K |
|
|
NINE
852
DELISTED
Nine Energy Service
NINE
| $271K | ﹤0.01% |
11,944
-17,590
| -60% | -$425K |
|
853
US Bancorp
USB
$98.9B
| $269K | ﹤0.01% |
5,590
-1,400
| -20% | -$70.2K |
|
854
Agilysys
AGYS
$2.93B
| $266K | ﹤0.01% |
12,550
-8,148
| -39% | -$151K |
|
|
AGTC
855
DELISTED
Applied Genetic Technologies Corporation
AGTC
| $265K | ﹤0.01% |
63,359
| – | – |
|
|
PCSB
856
DELISTED
PCSB Financial Corporation
PCSB
| $262K | ﹤0.01% |
+13,402
| New | +$269K |
|
|
NPKI
857
NPK International
NPKI
$1.19B
| $260K | ﹤0.01% |
28,400
-375,599
| -93% | -$3.22M |
|
858
Barnes & Noble Education
BNED
$440M
| $257K | ﹤0.01% |
613
+466
| +317% | +$253K |
|
859
Flotek Industries
FTK
$876M
| $255K | ﹤0.01% |
13,100
-101,045
| -89% | -$1.65M |
|
|
CSS
860
DELISTED
CSS Industries, Inc.
CSS
| $255K | ﹤0.01% |
42,525
+24,087
| +131% | +$195K |
|
|
CDTX
861
DELISTED
Cidara Therapeutics
CDTX
| $254K | ﹤0.01% |
4,799
-1,285
| -21% | -$70.5K |
|
862
WSFS Financial
WSFS
$4.15B
| $251K | ﹤0.01% |
6,493
-8,167
| -56% | -$340K |
|
863
Aviat Networks
AVNW
$265M
| $250K | ﹤0.01% |
32,494
+4,102
| +14% | +$28.8K |
|
|
ALNA
864
DELISTED
Allena Pharmaceuticals
ALNA
| $250K | ﹤0.01% |
+35,557
| New | +$258K |
|
865
Culp Inc
CULP
$45.2M
| $248K | ﹤0.01% |
+12,880
| New | +$240K |
|
|
BRSS
866
DELISTED
Global Brass & Copper Hldgs, Inc
BRSS
| $241K | ﹤0.01% |
+7,000
| New | +$217K |
|
867
Choice Hotels
CHH
$5.16B
| $240K | ﹤0.01% |
3,090
-2,730
| -47% | -$212K |
|
|
DZSI
868
DELISTED
DZS Inc. Common Stock
DZSI
| $240K | ﹤0.01% |
+22,493
| New | +$284K |
|
|
NSTG
869
DELISTED
NanoString Technologies, Inc.
NSTG
| $239K | ﹤0.01% |
10,000
-24,626
| -71% | -$566K |
|
870
Donnelley Financial Solutions
DFIN
$1.26B
| $238K | ﹤0.01% |
16,010
+2,200
| +16% | +$33.1K |
|
871
H.B. Fuller
FUL
$3.03B
| $238K | ﹤0.01% |
+4,890
| New | +$234K |
|
872
Vanda Pharmaceuticals
VNDA
$318M
| $237K | ﹤0.01% |
12,900
-84,635
| -87% | -$1.93M |
|
873
Vaalco Energy
EGY
$558M
| $236K | ﹤0.01% |
105,150
-20,800
| -17% | -$43.7K |
|
874
OraSure Technologies
OSUR
$274M
| $230K | ﹤0.01% |
20,660
-500
| -2% | -$5.79K |
|
875
IES Holdings
IESC
$12B
| $229K | ﹤0.01% |
12,889
| – | – |
|
Similar funds
OAG
CHP
SAM
JG
Jacobs Levy Equity Management's Q1 2019 Portfolio in Review
As of Q1 2019, Jacobs Levy Equity Management held 1,110 positions worth $6.93B, up 22% from $5.69B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
Jacobs Levy Equity Management deployed $454M of net new capital in Q1 2019, opening 146 new positions and adding to 497 existing holdings. Its largest new stake was AbbVie: 282,010 shares worth $22.7M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 20% a quarter earlier, followed by Financials and Consumer Discretionary.
On the sell side, the largest reduction was Wellcare Health Plans, Inc., an estimated $52.7M trimmed.
- Jacobs Levy Equity Management's largest Q1 2019 buy was AbbVie: 282,010 shares worth $22.7M.
- Jacobs Levy Equity Management added most to NVR in Q1 2019, an estimated $34.9M increase.
- Jacobs Levy Equity Management's biggest Q1 2019 reduction was Wellcare Health Plans, Inc., cutting an estimated $52.7M.
- Jacobs Levy Equity Management fully exited Celgene Corp in Q1 2019, selling an estimated $55.8M.
- Jacobs Levy Equity Management's ten largest holdings make up 16% of its $6.93B portfolio in Q1 2019.
- Jacobs Levy Equity Management opened 146 new positions and closed 160 in Q1 2019.
- Jacobs Levy Equity Management's portfolio value rose 22% quarter-over-quarter to $6.93B.
Based on Jacobs Levy Equity Management's 13F filing for Q1 2019, filed 14 May 2019.